A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2

The anti-VEGF antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Theoretically, vascular endothelial growth factor receptors (VEGFRs)-specific cytotoxic T lymphocytes (CTLs) can kill both tumor vessel cells and tumor cells expressing VEGFRs. Here we show an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Ryota, Fujioka, Masato, Morimoto, Yukina, Ohara, Kentaro, Kosugi, Kenzo, Oishi, Yumiko, Sato, Mizuto, Ueda, Ryo, Fujiwara, Hirokazu, Hikichi, Tetsuro, Noji, Shinobu, Oishi, Naoki, Ogawa, Kaoru, Kawakami, Yutaka, Ohira, Takayuki, Yoshida, Kazunari, Toda, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917794/
https://www.ncbi.nlm.nih.gov/pubmed/31848332
http://dx.doi.org/10.1038/s41467-019-13640-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917794/
https://www.ncbi.nlm.nih.gov/pubmed/31848332
http://dx.doi.org/10.1038/s41467-019-13640-1

Ejemplares similares